While Pfizer Inc. has long been the king of the big pharmas, the company's $3.6 billion bid for King Pharmaceuticals Inc. may be the card it needs to play a larger role in the pain therapeutics space. (BoWorld Today)

SAN FRANCISCO – In a limited capital market where biotechs are essentially back to "begging, borrowing or stealing," the most obvious business model for staying afloat is partnering, whether with academia, government, foundations or big pharma, said Andrew Schwab, founder and managing partner at 5AM Ventures. (BioWorld Today)

WASHINGTON – The National Institutes of Health (NIH) can continue to support human embryonic stem cell (hESC) research while the government fights a lawsuit challenging the Obama administration's funding policies, an appeals court ruled late Tuesday. (BioWorld Today)

The prostate cancer therapy arena was dealt two blows this week, with Pfizer Inc.'s Sutent (sunitinib malate) and AstraZeneca plc's zibotentan both failing to demonstrate an improvement in overall survival. (BioWorld Today)

Shares of Seattle Genetics Inc. leaped 17.6 percent Monday after the firm revealed striking top-line pivotal trial results showing that 75 percent of patients with relapsed-refractory Hodgkin's lymphoma (HL) receiving single agent brentuximab vedotin (SGN-35) achieved an objective response, with a median duration of more than six months. (BioWorld Today)